CUE

I am initiating Cue Biopharma with a "Buy" rating, driven by positive phase 2 results for CUE-221 in chronic spontaneous urticaria [CSU]. CUE-221's novel dual mechanism of action demonstrated superior efficacy to XOLAIR, with 54% of patients achieving complete hive resolution at 12 weeks [p < 0.005]. Upcoming catalysts include 36-week PK and IgE data in 2026, and planned phase 2b/3 global studies in CSU and food allergy, targeting large market opportunities.

Cue Biopharma, Inc. (CUE) Discusses Positive Phase II Top Line Results for CUE-221 in Chronic Spontaneous Urticaria Transcript

NEW YORK, Aug. 24, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Cue Biopharma, Inc. (NASDAQ: CUE) on behalf of the company's shareholders.  The investigation seeks to determine whether Cue Biopharma's directors breached their fiduciary duties in connection with recent corporate actions.

BOSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical stage biopharmaceutical company targeting transformative therapies for immune-mediated diseases, today reported second quarter 2026 financial results as well as recent business highlights.

BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company targeting transformative therapies for immune-mediated diseases, today announced the appointment of James M. Ahlers as Chief Financial Officer.

Physician-scientist and immunology leader joins Cue as the company advances key clinical programs in allergic and autoimmune diseases Physician-scientist and immunology leader joins Cue as the company advances key clinical programs in allergic and autoimmune diseases

BOSTON, July 09, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical stage biopharmaceutical company focused on developing transformative therapies targeting functional cures for immunological disorders, today announced that it has entered into a securities purchase agreement with a group of accredited investors for the private placement of (i) 1,418,071 shares of common stock at a purchase price of $33.21 per share and (ii) to certain investors, in lieu of shares of common stock, pre-funded warrants to purchase up to 87,500 shares of common stock at a price per pre-funded warrant of $33.209, for gross proceeds of approximately $50.0 million.

Daniel Camardo, former CEO and executive commercial leader with a track record of successful launches joins the board Viola Meehan, former CFO with broad experience in governance, strategic finance and executive leadership joins the board  BOSTON, June 02, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a precision immuno-engineering company focused on developing transformative therapies targeting functional cures for immunological disorders, today announced the transition of its board as the Company continues its strategic growth and transformation to support late clinical stage capabilities and activities. Effective May 29, 2026, four independent directors, Jill Broadfoot, Peter Kiener, Frank Morich, and Patrick Verheyen, have resigned from the board.

BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage therapeutics company focused on developing transformative therapies targeting functional cures for immunological disorders, today announced that Shao-Lee Lin, president and chief executive officer, will present at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026 at 3:10 p.m. EDT in New York City.

Moves designed to strengthen leadership and financial position, advance portfolio, and leverage expertise in precision immunoengineering Moves designed to strengthen leadership and financial position, advance portfolio, and leverage expertise in precision immunoengineering